Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Ginsenoside Rh2

Catalog No: tcsc3835

Available Sizes

Size: 5mg

Size: 10mg

Specifications

CAS No:
78214-33-2

Formula:
$C_{36}H_{62}O_8$

Pathway:
Apoptosis;Apoptosis

Target:
Apoptosis;Caspase

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 300 mg/mL (481.64 mM)

Alternative Names:
20(S)-Ginsenoside Rh2;20(S)-Rh2;Ginsenoside-Rh2

Observed Molecular Weight:
622.87

Product Description

Ginsenoside Rh2 is isolated from the root of *Ginseng*. Ginsenoside Rh2 induces the activation of **caspase-8** and **caspase-9**. Ginsenoside Rh2 induces cancer cell **apoptosis** in a multi-path manner.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 & Target: Caspase-8 and Caspase-9[1]

Apoptosis[1]

In Vitro: Ginsenoside Rh2 induces the activation of two initiator caspases, caspase-8 and caspase-9 in human cancer cells. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner and is therefore a promising candidate for anti-tumor drug development. Ginsenoside Rh2 triggers p53-dependent Fas expression and consequent activation of caspase-8 and p53-independent caspase-9-mediated intrinsic pathway to cause cancer cell death.The cytotoxic activity of Ginsenoside Rh2 in the human tumor cell lines HeLa, SK-HEP-1, SW480, and PC-3 is assessed by MTT. The cell viability of HeLa cells is remarkably inhibited by Ginsenoside Rh2, with an IC_{50} value of 2.52 μg/mL, whereas SK-HEP-1 and SW480 cells are less sensitive to Ginsenoside Rh2, with IC_{50} values of 3.15 μg/mL and 4.06 μg/mL, respectively. PC-3 cells are the least vulnerable to Ginsenoside Rh2, with an IC_{50} value of 7.85 μg/mL, 3-fold higher than HeLa cells[1].

In Vivo: A total of 15 days following B16-F10 cell injection, tumor sizes from the 3 tumor bearing groups are measured. The tumor sizes in the G-L group and G-H group (G-L and G-H refer to a low or high dose of ginsenoside Rh2 injection) are reduced compared with the tumor group (P[2].